Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5353984 | 0.84 | MAPT (0.33) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3739493 | 0.84 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL29527999 | 0.82 | ALDH1A1 (0.37) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL28754170 | 0.82 | ALDH1A1 (0.37) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL3747840 | 0.81 | GAA (0.44) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL30546824 | 0.78 | MAPT (0.34) | PARP1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12391733 | 0.78 | MAPT (0.33) | PARP1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3743974 | 0.71 | PARP1 (0.40) | PARP1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL261162 | 0.71 | PARP1 (0.50) | PARP1KDM4E | |
| SCHEMBL30521167 | 0.71 | PARP1 (0.50) | PARP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0332104-A2 | Chemically regulatable DNA sequences and genes and uses thereof | CIBA-GEIGY AG (CH) | 1989-09-13 | — | — | EP | claimed |
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-8642633-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8481810-B2 | Transgenic plants expressing a cellulase | SYNGENTA PARTICIPATIONS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8404682-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2012-02-09 | — | — | US | disclosed |
| US-8013003-B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | CORTEX PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7838732-B2 | Transgenic plants expressing a cellulase | SYNGENTA PARTICIPATIONS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC | 2010-05-13 | — | — | US | disclosed |
| US-5777200-A | Chemically regulatable and anti-pathogenic DNA sequences and uses thereof | NOVARTIS FINANCE CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998026082-A1 | METHODS OF USING THE NIM1 GENE TO CONFER DISEASE RESISTANCE IN PLANTS | NOVARTIS AG (CH) | 1998-06-18 | — | — | WO | disclosed |
| US-5767369-A | PLANT RESISTANCE | NOVARTIS FINANCE CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1998011235-A2 | TRANSGENIC PLANTS EXPRESSING CELLULOLYTIC ENZYMES | NOVARTIS AG (CH) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998003536-A1 | CHEMICALLY-INDUCIBLE ARABIDOPSIS PR-1 PROMOTER | NOVARTIS AG (CH) | 1998-01-29 | — | — | WO | disclosed |
| US-5689044-A | GENETIC ENGINEERING | NOVARTIS CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| US-5654414-A | GENETIC ENGINEERING | NOVARTIS FINANCE CORPORATION (US) | 1997-08-05 | — | — | US | disclosed |
| US-5650505-A | Chemically regulatable and anti-pathogenic DNA sequences and uses thereof | NOVARTIS CORPORATION (US) | 1997-07-22 | — | — | US | disclosed |
| US-5614395-A | SCREENING FOR AGROCHEMICALS HAVING THE ABILITY TO INDUCE SYSTEMIC ACQUIRED RESISTANCE IN PLANTS | CIBA-GEIGY CORPORATION (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0332104-A2 | Chemically regulatable DNA sequences and genes and uses thereof | CIBA-GEIGY AG (CH) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035173-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN2A, GRIN2B, SLC18A2 | PARP1 4504/4885MEN1 4743/4885KMT2A 1571/4885 |
| US-20100120764-A1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | DRD2, DRD3, GAP43 | PARP1 3963/4885MEN1 4801/4885KMT2A 1763/4885 |
| US-20130137733-A1 | Di-Substituted Amides for Enhancing Glutamatergic Synaptic Responses | DRD2, DRD3, GAP43 | PARP1 3963/4885MEN1 4801/4885KMT2A 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.